These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8595788)

  • 41. Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group.
    Sachdeo RC; Leroy RF; Krauss GL; Drake ME; Green PM; Leppik IE; Shu VS; Ringham GL; Sommerville KW
    Arch Neurol; 1997 May; 54(5):595-601. PubMed ID: 9152116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tiagabine: new preparation. Refractory partial epilepsy: another alternative.
    Prescrire Int; 1998 Aug; 7(36):99-101. PubMed ID: 10342943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Characteristics and indications of tiagabine].
    Casas-Fernández C; Domingo-Jiménez R
    Rev Neurol; 2002 Sep; 35 Suppl 1():S96-S100. PubMed ID: 12373661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tiagabine add-on for drug-resistant partial epilepsy.
    Pereira J; Marson AG; Hutton JL
    Cochrane Database Syst Rev; 2002; (3):CD001908. PubMed ID: 12137637
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transient athetosis induced by tiagabine.
    Tombini M; Pacifici L; Passarelli F; Rossini PM
    Epilepsia; 2006 Apr; 47(4):799-800. PubMed ID: 16650148
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of twice- and three times daily tiagabine for the adjunctive treatment of partial seizures in refractory patients with epilepsy: an open label, randomised, parallel-group study.
    Biraben A; Beaussart M; Josien E; Pestre M; Savet JF; Schaff JL; Tourniaire D; Sevestre M; Renault-Djouadi J
    Epileptic Disord; 2001 Jun; 3(2):91-100. PubMed ID: 11431171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood.
    Dodrill CB; Arnett JL; Deaton R; Lenz GT; Sommerville KW
    Epilepsy Res; 2000 Dec; 42(2-3):123-32. PubMed ID: 11074185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin.
    Hogan RE; Bertrand ME; Deaton RL; Sommerville KW
    Epilepsy Res; 2000 Aug; 41(1):23-8. PubMed ID: 10924865
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy.
    Ettinger AB; Bernal OG; Andriola MR; Bagchi S; Flores P; Just C; Pitocco C; Rooney T; Tuominen J; Devinsky O
    Epilepsia; 1999 Aug; 40(8):1159-62. PubMed ID: 10448832
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Tiagabine: a GABA-ergic anti-epileptic drug].
    Herranz JL
    Rev Neurol; 1997 Oct; 25(146):1607-10. PubMed ID: 9462992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Long-term safety of using tiagabine in epilepsy].
    Kozik A
    Neurol Neurochir Pol; 2000; 34 Suppl 7():17-22; discussion 22-3. PubMed ID: 11253488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Status epilepticus and tiagabine therapy revisited.
    Koepp MJ; Edwards M; Collins J; Farrel F; Smith S
    Epilepsia; 2005 Oct; 46(10):1625-32. PubMed ID: 16190934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study.
    Elger CE; Brodie MJ; Anhut H; Lee CM; Barrett JA
    Epilepsia; 2005 Dec; 46(12):1926-36. PubMed ID: 16393158
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management strategies for refractory localization-related seizures.
    Brodie MJ
    Epilepsia; 2001; 42 Suppl 3():27-30. PubMed ID: 11520319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term effects of tiagabine monotherapy on cognition and mood in adult patients with chronic partial epilepsy.
    Aikiä M; Jutila L; Salmenperä T; Mervaala E; Kälviäinen R
    Epilepsy Behav; 2006 Jun; 8(4):750-5. PubMed ID: 16647884
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tiagabine pharmacology in profile.
    Brodie MJ
    Epilepsia; 1995; 36 Suppl 6():S7-S9. PubMed ID: 8595791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures.
    Hosford DA; Wang Y
    Epilepsia; 1997 Apr; 38(4):408-14. PubMed ID: 9118845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Current data on tiagabine].
    Herranz JL
    Rev Neurol; 2000 Jun; 30 Suppl 1():S137-41. PubMed ID: 10904981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Open study with tiagabine in partial epilepsy].
    Arroyo S
    Rev Neurol; 2000 Oct 16-31; 31(8):728-32. PubMed ID: 11082879
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tolerability of tiagabine: a prospective open-label study.
    Bauer J; Bergmann A; Reuber M; Stodieck SR; Genton P
    Epileptic Disord; 2002 Dec; 4(4):257-60. PubMed ID: 12600812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.